NEBNext Direct™ for target enrichment
NEBNext Direct employs a unique technology that enables highly specific target enrichment of genomic regions of interest.
The result of a partnership between New England Biolabs and Directed Genomics™, this innovative approach to target enrichment balances the speed and precision of multiplexed PCR-based approaches with the content scalability typical of hybridization-based methods.
This flexibility allows a single workflow for assays ranging from single gene tests to comprehensive panels including several hundred genes.
Regardless of sample type or assay content, NEBNext Direct allows you to enrich your targets with precision.
- Generate a higher percentage of your sequencing reads aligning to your targets
- Eliminate the need to over-sequence, reducing cost per sample
- Obtain uniform sequencing of ALL targets, regardless of GC content
- Save time with a streamlined workflow that couples enrichment and library preparation
- Generate high quality libraries with limited input amounts and degraded DNA samples, including FFPE and ctDNA
- Distinguish molecular duplicates, reducing false positive variants and improving sensitivity
- On-bead sample preparation is ideal for automated workflows
Learn more about NEBNext Direct and this innovative approach to target enrichment for next-generation sequencing.
„Using the NEBNext Direct kit, we were able to detect all known single nucleotide variants and indels in DNA extracted from fresh frozen or FFPE tissue derived from glioma biopsies. We could also clearly see amplification in genes like EGFR or PDGFR. The workflow is really easy and fast and can be rapidly implemented in a lab.“
Yannick Marie, Sequencing Core Facility Manager, Brain and Spine Institute (ICM)
„The kit and its technology are easy to use and easy to automate, allowing us to get up and running quickly. The protocol itself is fast and efficient to obtain deep coverage of targets, giving homogeneous results for FFPE and frozen tumors, therefore opening doors for customized panels.“
Francis Rousseau, Ph.D., Director of Genomics for IntegraGen SA